- Home
- ISRL vs TCRX Comparison
ISRL vs TCRX Comparison
Compare ISRL & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISRL
- TCRX
- Stock Information
- Founded
- ISRL 2021
- TCRX 2018
- Country
- ISRL United States
- TCRX United States
- Employees
- ISRL N/A
- TCRX N/A
- Industry
- ISRL Blank Checks
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- ISRL Finance
- TCRX Health Care
- Exchange
- ISRL Nasdaq
- TCRX Nasdaq
- Market Cap
- ISRL 145.6M
- TCRX 170.1M
- IPO Year
- ISRL 2023
- TCRX 2021
- Fundamental
- Price
- ISRL $11.36
- TCRX $2.40
- Analyst Decision
- ISRL
- TCRX Strong Buy
- Analyst Count
- ISRL 0
- TCRX 5
- Target Price
- ISRL N/A
- TCRX $11.40
- AVG Volume (30 Days)
- ISRL 35.6K
- TCRX 544.4K
- Earning Date
- ISRL 01-01-0001
- TCRX 03-05-2025
- Dividend Yield
- ISRL N/A
- TCRX N/A
- EPS Growth
- ISRL N/A
- TCRX N/A
- EPS
- ISRL 0.26
- TCRX N/A
- Revenue
- ISRL N/A
- TCRX $9,362,000.00
- Revenue This Year
- ISRL N/A
- TCRX N/A
- Revenue Next Year
- ISRL N/A
- TCRX $5.14
- P/E Ratio
- ISRL $43.53
- TCRX N/A
- Revenue Growth
- ISRL N/A
- TCRX N/A
- 52 Week Low
- ISRL $10.69
- TCRX $2.38
- 52 Week High
- ISRL $11.50
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- ISRL 51.41
- TCRX 25.27
- Support Level
- ISRL $11.30
- TCRX $2.60
- Resistance Level
- ISRL $11.50
- TCRX $2.85
- Average True Range (ATR)
- ISRL 0.02
- TCRX 0.17
- MACD
- ISRL 0.00
- TCRX 0.00
- Stochastic Oscillator
- ISRL 30.00
- TCRX 2.41
About ISRL Israel Acquisitions Corp
Israel Acquisitions Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.